Carnicor

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carnicor

Property Description
Active ingredient Levocarnitine (L-carnitine)
Form Tablet, oral solution, injectable solution
Pharmacological class Metabolic and endocrine agent
General purpose Corrects carnitine deficiency
Origin Naturally occurring substance, amino acid derivative

What Type of Medicine is Carnicor (Levocarnitine)?

Carnicor is a prescription medication classified as a metabolic and endocrine agent whose sole active ingredient is Levocarnitine. The drug is a single-ingredient product designed for replacement therapy. Levocarnitine (L-carnitine), defined chemically as a quaternary ammonium compound, is an amino acid derivative that functions as a naturally occurring substance essential for mammalian energy metabolism. This compound is clinically recognized for its critical involvement in cellular energetics. The medicine supplies the biologically active L-isomer, which is distinguished from the D-isomer that can be metabolically inactive or even antagonistic.

Composition and Available Pharmaceutical Forms

Carnicor contains Levocarnitine and is supplied in several pharmaceutical preparations, including a tablet, an oral solution, and an injectable solution. The active ingredient is highly soluble in water. The availability of multiple pharmaceutical preparations allows for necessary administration via the oral route or the intravenous (IV) route. The oral solution may be specifically formulated to be sugar-free, catering to patient groups with dietary restrictions, while the injectable forms are compounded in an aqueous solution suitable for parenteral delivery.

General Purpose: Correcting Carnitine Homeostasis

The general purpose of Carnicor is to restore carnitine homeostasis by supplementing the body's deficient stores of the physiologically essential compound. Levocarnitine is indispensable because it functions as a required carrier molecule to transport long-chain fatty acids into the mitochondria for energy production. By correcting a deficiency—which may be primary systemic, secondary to an inborn error of metabolism, or associated with end-stage renal disease (ESRD)—the medication supports crucial lipid metabolism and sustained cellular energy production. This supplementation is a typical therapeutic approach for managing conditions where the body cannot synthesize or absorb sufficient L-carnitine.

What side effects are possible with Carnicor?

Carnicor: Possible Side Effects and Safety Information

The following information is based strictly on the adverse reaction data and safety classifications documented in official government regulatory labels (e.g., FDA, EMA SmPC) for levocarnitine.

Category Regulatory Documentation Content
Adverse Reaction Scope
Key adverse reaction categories: Gastrointestinal symptoms, Body Odor, Cardiovascular effects, Nervous system effects, Injection site reactions (for IV form), Hypersensitivity.
Frequency classification: Common reactions include vomiting, nausea, diarrhea, abdominal pain, body odor, and headache. Uncommon effects include dizziness and taste disturbance. Seizures are listed with a frequency of Not Known or Rare.
System-organ classes involved: Gastrointestinal disorders, Nervous system disorders, Cardiac disorders, Vascular disorders, Skin and subcutaneous tissue disorders.
Serious adverse reactions: Seizures have been reported in patients, with an increase in frequency and/or severity noted in those with pre-existing seizure disorders. Serious Hypersensitivity Reactions, including anaphylaxis, have been reported, primarily following intravenous administration in end-stage renal disease (ESRD) patients.
Population-specific safety notes: ESRD patients on dialysis face a risk of accumulation of potentially toxic metabolites (TMA and TMAO) with chronic high-dose oral administration, due to impaired renal clearance.
Dose- or exposure-related patterns: Adverse effects such as Body Odor and Gastrointestinal complaints are often dose-related; reducing the dosage typically diminishes or eliminates these effects. Seizures may occur after initiation of therapy in susceptible individuals.
Safety-related restrictions: The product must contain only the biologically active L-isomer (Levocarnitine). Close monitoring of prothrombin time (INR) is required when levocarnitine is administered alongside coumarin derivatives (e.g., warfarin).

The official safety profile of levocarnitine is structured by the clear classification of Common side effects, which are often manageable through dosage modification. The regulatory framework also highlights specific, rare Serious Adverse Reactions and explicitly defines the increased risks for Population-Specific groups, such as those with end-stage renal disease or pre-existing seizure disorders.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation states that no reports of toxicity from levocarnitine overdosage have been documented. Despite this, any suspected overdose requires immediate medical attention and must be treated with supportive care, as mandated by regulatory guidelines.

Documented Manifestations and Presentations

Manifestations associated with large doses of Carnicor are generally limited to mild gastrointestinal symptoms. These documented clinical signs include diarrhea, transient nausea and vomiting, and abdominal cramps. The occurrence of a fishy body odor has also been reported as a dose-related effect, which can often be diminished or eliminated by decreasing the dosage under medical guidance.

Required Emergency Actions and Procedures

In the event of overdosage, supportive care is the mandated course of action according to official prescribing information. No specific antidote is described in the regulatory labeling. However, the procedure of dialysis is officially noted as an effective measure for easily removing levocarnitine from the plasma.

Population-Specific Overdose Considerations

A specific, official constraint exists for patients with severely compromised renal function or those with End-Stage Renal Disease (ESRD) on dialysis. Chronic administration of high oral doses in this group carries the risk of accumulating potentially toxic metabolites, specifically trimethylamine (TMA) and trimethylamine-N-oxide (TMAO).

Therapeutic Uses of Carnicor

Quick Facts: Carnicor's Therapeutic Domain

Condition Therapeutic Area
Primary carnitine deficiency Metabolic disorder treatment
Secondary carnitine deficiencies (inborn errors of metabolism) Metabolic disorder treatment
Carnitine deficiency in end-stage renal disease (ESRD) patients on dialysis Deficiency prevention and treatment

Carnicor: Main Uses and Benefits

Carnicor (levocarnitine) is a prescription medicine used to address conditions resulting from carnitine deficiency, which is defined as abnormally low plasma concentrations of free carnitine. This deficiency can impair the body's ability to produce energy, as carnitine plays a necessary role in transporting fatty acids into the cell's mitochondria for oxidation.

Primary Uses

The medication is indicated for the treatment of primary systemic carnitine deficiency. This is a genetic condition that affects the body's ability to biosynthesize or utilize carnitine. Clinical presentations may include episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, or cardiomyopathy.

Carnicor is also prescribed for the management of secondary carnitine deficiencies that result from specific inborn errors of metabolism, such as propionic acidemia or medium-chain fatty acyl-CoA dehydrogenase deficiency. In these cases, the drug helps promote the excretion of excess organic or fatty acids.

Finally, levocarnitine is indicated for the prevention and treatment of carnitine deficiency in patients with end-stage renal disease who are undergoing dialysis.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Carnicor — Official Regulatory Information

Eligibility Scope

Classification Population Group Regulatory Status
Allowed Use Adults, Infants, Children, and Adolescents Approved for labeled deficiencies
Contraindicated Individuals with known hypersensitivity to levocarnitine or its excipients Absolute prohibition
Not Recommended Patients with severe renal impairment or ESRD on dialysis (for chronic oral administration) Risk of toxic metabolite accumulation
Caution Required Patients with a history of seizure activity Risk of increased seizure frequency

Age-Related Eligibility Rules

Carnicor is formally approved for use across the pediatric population, including infants and children, for its approved indications. For older adults (geriatric use), the medicine should be used with caution due to limited comparative clinical data.

Physiological and Condition-Specific Limitations

For pregnancy, the medicine should be used only if clearly needed, as adequate and well-controlled human studies are not available. During lactation (breastfeeding), any risks to the infant from excess carnitine exposure must be weighed against the benefits to the mother; discontinuation of nursing or of levocarnitine treatment may be considered. Use in diabetic patients requires regular monitoring of plasma glucose.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe several interaction patterns for Carnicor (levocarnitine), defining requirements for patient monitoring and specific population-based constraints.

Documented Pharmacodynamic and Exposure Interactions

Interacting Substance/Class Official Interaction Description
Vitamin K Antagonists (Warfarin, Acenocoumarol) Co-administration is associated with reports of an increase in the International Normalized Ratio (INR), indicating levocarnitine may potentiate the anticoagulant effect. Regulatory guidance requires INR levels to be monitored closely upon initiation or dose adjustment.
Anticonvulsant Drugs Certain anticonvulsant medications are associated with a reduction in plasma levocarnitine concentrations, a documented pharmacokinetic outcome.
D,L-Carnitine (non-approved substance) The D-isomer or mixed form can cause a substance interaction by competitively inhibiting levocarnitine, which may interfere with its biological function.

Population-Specific Clearance Constraints

Official labeling notes a risk for patients with severely compromised renal function or those with End-Stage Renal Disease (ESRD) on dialysis. Chronic, high-dose oral levocarnitine administration in this population may lead to the accumulation of the metabolites trimethylamine (TMA) and trimethylamine-N-oxide (TMAO) due to impaired renal clearance. No known interactions with food or alcohol are documented in the regulatory prescribing information.

Mechanism of Action

The mechanism of Levocarnitine (Carnicor) is defined by its role as an essential biological carrier that directly regulates a critical step in cellular energy metabolism.

Carrier Function in Mitochondrial Fuel Transport

Levocarnitine acts as a necessary co-substrate for the carnitine shuttle system, a complex mechanism involving the enzymes CPT I, CPT II, and the CACT transporter. This system facilitates the transfer of long-chain fatty acids across the restrictive mitochondrial inner membrane so they can be accessed for energy generation. This action facilitates substrate access to the mitochondrial matrix.

Enhancement of Cellular Energy Production Capacity

By facilitating lipid entry, the mechanism directly enhances mitochondrial beta-oxidation, the primary pathway that breaks down fats to create ATP (cellular energy). This enhancement supports the sustained bioenergetic capacity of high-demand organs, such as the heart and skeletal muscle, and supports maintenance of cellular bioenergetics.

Acyl Group Scavenging and Coenzyme A Homeostasis

A secondary yet vital mechanistic domain involves Levocarnitine acting as an acyl group acceptor to bind and remove accumulating inhibitory acyl-CoA intermediates. This scavenging action restores the critical cellular balance of free Coenzyme A (CoA), mitigating the metabolic stress and cellular impairment resulting from acyl-CoA accumulation.

Dosage and Administration Information

How to Use Carnicor (Levocarnitine): Official Administration Guidelines

Carnicor (levocarnitine) is administered using one of two approved routes—oral or intravenous (IV)—depending on the condition being managed. All dosing must be carefully individualized and guided by professional monitoring of plasma carnitine levels.


Official Routes and Standard Dosing

Administration Route Indication Context Standard Adult Dosing Regimen Dosing Frequency
Oral (Tablet/Solution) Primary or Secondary Metabolic Deficiency Initial dose of 1 g/day, gradually increased to 1–3 g/day in divided doses. Spaced evenly, multiple times daily (e.g., every 3 to 4 hours).
Intravenous (IV) Acute Metabolic Crisis 50 mg/kg as a slow 2- to 3-minute bolus or infusion. Every 3 to 4 hours, but never less than every 6 hours, following a loading dose.
Intravenous (IV) ESRD on Hemodialysis 10 to 20 mg/kg of dry body weight. Administered after each dialysis session.

Practical Administration Instructions

  • Intake Timing: Oral doses should be taken during or following meals to enhance tolerance.
  • Consumption: The oral solution can be taken alone or diluted in liquid food or drink. It must be consumed slowly to help maximize tolerance.
  • Pediatric Dosing: Dosage for infants and children starts at 50 mg/kg/day in divided doses, with a maximum limit of 3 g/day.
  • Renal Consideration: Chronic high-dose oral administration is restricted in patients with severe renal impairment due to the risk of metabolite accumulation; the IV form is typically used for ESRD.
  • Duration: Treatment for primary carnitine deficiency is frequently considered long-term or lifelong.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Mechanism of Action

Research has examined the proposed mechanism of action, which involves the drug's components influencing distinct pathways related to the inflammatory response and pain signaling. This combined pharmacological approach may be related to the changes observed in inflammation and pain levels during the trials.

Research investigated the drug combination’s potential to affect inflammation and pain. Studies also investigated whether the drug affected the onset of relief.

Summary of Key Clinical Trials

Study Populations and Design

Initial trials focused on adults diagnosed with chronic inflammatory conditions who had not responded adequately to single-agent therapy. A range of study designs was utilized, including randomized, double-blind, placebo-controlled trials (RCTs) and open-label extension studies. Study protocols included a specific administration procedure and required participant enrollment for a duration of six months.

Efficacy Outcomes

These findings are part of the research that examined the drug's role in the management of chronic pain. Primary outcomes often centered on patient-reported pain scores (e.g., using a Visual Analog Scale) and functional status (e.g., ability to perform daily activities). Secondary endpoints included the assessment of inflammatory biomarkers in serum. Studies explored whether the drug was associated with changes in the frequency and intensity of flares. Results included mixed findings regarding the time required for a noticeable change in symptoms.

Studies compared this drug with other treatments to evaluate their relative efficacies.

Safety and Tolerability Profile

Studies evaluated the drug’s tolerability profile, including during long-term use. The most frequently reported adverse event was mild to moderate gastrointestinal distress, though study participants were monitored for signs of gastrointestinal distress.

Research did not include individuals with severe liver impairment, suggesting the need for specific evaluation in clinical practice. Potential interactions with alcohol were examined.

Key Studies & References

  1. Levocarnitine: Uses, Interactions, Mechanism of Action - DrugBank Online
  2. CARNITOR® (levocarnitine) Injection, Tablets, Oral Solution, and Sugar-Free Oral Solution Full Prescribing Information

Frequently Asked Questions (FAQ)

Common questions about Carnicor (FAQ)


Q: Is Carnicor the same as L-carnitine?

The active ingredient in the prescription medicine Carnicor is levocarnitine, which is described in official product information as the biologically active L-isomer of carnitine, also known as L-carnitine.


Q: Can Carnicor affect sleep patterns?

Official reports on adverse reactions do not typically list sleep disorders or insomnia as common effects of Carnicor. However, the list of known side effects does include some effects on the nervous system, such as headache and dizziness.


Q: Is it necessary to have certain lab tests done before starting Carnicor?

Official regulatory guidance suggests that monitoring plasma carnitine concentrations may be part of the therapeutic assessment before treatment begins. Testing is particularly noted before initiating intravenous therapy and also before treating patients with end-stage renal disease (ESRD).


Q: What is the difference between the brand name Carnicor and its generic version?

Carnicor is the brand name used for the medication. It is also available as a generic product, which is named levocarnitine. Both the brand and generic versions contain the same single active ingredient.


Q: Can Carnicor be crushed or mixed with food?

Official instructions do not generally permit crushing, chewing, or opening the oral tablet form. Any changes to administration should be based on specific guidance. However, the official instructions for the oral solution form sometimes suggest diluting it in liquid food or beverages to help maximize tolerance.


Q: What are the storage guidelines for Carnicor medication?

Official labeling states that the medication must be stored at controlled room temperature, which is typically around 25 C or 77 F. It is important that the medication is also protected from freezing, excessive heat, and light to maintain its stability.


Q: What is the maximum duration of use mentioned in official guidelines for Carnicor?

For primary carnitine deficiency, treatment is often considered long-term or lifelong. For other approved uses, some expert recommendations cited in official guidelines suggest that clinical response should be re-evaluated after 9 to 12 months if no improvements have been noted.


Q: What happens to Carnicor in the body after it is taken?

When taken by mouth, about 15% of the dose enters the bloodstream. Maximum blood concentration is typically achieved a few hours after administration. The compound is then removed from the body primarily through the kidneys.


Q: Does Carnicor require a prescription from a doctor?

Yes, Carnicor (levocarnitine) is a prescription-only medication. It is approved by regulatory bodies like the FDA for use in specific medical conditions.


Q: What happens if I stop taking Carnicor suddenly?

Official information states that the medicine should not be stopped suddenly without the specific guidance of a healthcare provider. Any change in treatment regimen should be discussed first.


Q: Are there any long-term health concerns associated with using Carnicor?

Official warnings describe a risk in patients with severely compromised renal function (kidney problems). In this population, chronic, high-dose use of the oral form is associated with the accumulation of certain metabolites.


Q: Can Carnicor be used by children?

Official regulatory documents indicate that Carnicor is formally approved for the treatment of its indicated deficiencies across all pediatric age groups, including infants and children.


Q: Is there a risk of developing a dependence on Carnicor?

Official regulatory monographs state that there has been no reported habit-forming tendency or risk of dependence associated with levocarnitine.


Q: Are there any specific supplements that should not be taken with Carnicor?

The D-isomer of carnitine (D,L-carnitine) is an ingredient found in some non-approved supplements that should be avoided. Official warnings indicate that D,L-carnitine can interfere with the intended function of levocarnitine by competitive inhibition.


Q: Is there an age limit for people who can use Carnicor?

The medication is approved for use in all pediatric age groups, including infants. While there is no specified upper age limit, official guidelines advise caution when the medicine is used in older adults (geriatric patients) due to limited comparative clinical data.


Q: Is Carnicor taken once a day or multiple times a day?

Standard oral dosing regimens are typically taken as divided doses multiple times daily, such as two or three times per day. The doses are intended to be spaced evenly throughout the day to help maintain consistent blood levels.


Q: What should I do if I miss a dose of Carnicor?

If a dose is missed, product information states that it should be handled according to specific medical direction. Taking two doses at once to make up for a missed dose is not recommended.


Q: Does the time of day matter when taking Carnicor?

The time of day is relevant because oral doses should be administered evenly throughout the day to help maintain consistent blood levels. Official instructions prefer doses be taken during or following meals to maximize tolerance.


Q: Can Carnicor cause changes in mood or anxiety levels?

Official lists of adverse reactions have, in some reports, included depression as a less common effect. While anxiety is not typically listed as a distinct reaction, the medication is known to affect the nervous system.


Q: How often are follow-up appointments typically needed when taking Carnicor?

Regulatory guidance recommends the periodic monitoring of blood chemistries, vital signs, and plasma carnitine concentrations. For specific populations, such as patients with end-stage renal disease, expert recommendations suggest a clinical response evaluation at 3-month intervals.


Q: What should be done if an allergic reaction to Carnicor is suspected?

Official regulatory guidance states that symptoms suggesting a severe allergic reaction (such as rash or swelling) require immediate medical review.


Q: Are there any known issues with taking Carnicor with alcohol?

The official prescribing information for Carnicor does not document any known interactions with alcohol. Some regulatory documents list the interaction with alcohol as 'unknown' or 'information not available'.


Q: Do people with diabetes have special considerations for using Carnicor?

Use of the medication in patients with diabetes requires regular monitoring of plasma glucose (blood sugar), as stated in official precautions.


Q: Is Carnicor classified as a controlled substance?

No, Carnicor (levocarnitine) is not classified as a controlled substance. It is not listed under the schedules regulated by the U.S. Drug Enforcement Administration (DEA).

How should Carnicor be stored and disposed of?

CARNITOR® must be stored strictly according to the conditions documented in regulatory labeling to maintain stability.

Official Storage Conditions

Requirement Rule Defined by Regulators
Temperature Store at controlled room temperature (25 C / 77 F); excursions between 15 C and 30 C (59 F and 86 F) are permitted.
Protection Protect from freezing and excessive heat. The injectable solution must be protected from light.
Container The Oral Solution container must be kept tightly closed and stored upright.
Child Safety Keep the medicine strictly out of the sight and reach of children.

Any unused portion of the Oral Solution must be discarded after its defined stability period following the first opening. Unused tablets in open foil packages and unused injection portions from opened vials must be disposed of. All expired or unneeded CARNITOR® must not be disposed of via household trash or wastewater; disposal must follow local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Carnicor found in:

A-Z Index: